Methods and compounds for treating paramyxoviridae virus infections

a technology of paramyxoviridae virus and compound, which is applied in the direction of drug composition, antibody medical ingredients, dispersed delivery, etc., can solve the problems of inability to prevent hpiv infection, inability to prevent hsv infection, and inability to provide a vaccine. , to achieve the effect of preventing hsv infection, preventing hsv infection, and preventing hsv infection

Inactive Publication Date: 2012-02-02
GILEAD SCI INC
View PDF3 Cites 55 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0511]The invention has been described with reference to various specific and preferred embodiments and techniques. However, one skilled in the art will understand that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Problems solved by technology

Currently, no vaccines are available to prevent HPIV infections.
No vaccine to prevent HRSV infection is currently available.
The monoclonal antibody palivizumab is available for infants at high risk, e.g., premature infants or those with either cardiac or lung disease, but the cost for general use is often prohibitive.
Ribavirin has also been used to treat HRSV infections but has limited efficacy.
However, no methods of treating Paramyxoviridae infections with these compounds have been disclosed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compounds for treating paramyxoviridae virus infections
  • Methods and compounds for treating paramyxoviridae virus infections
  • Methods and compounds for treating paramyxoviridae virus infections

Examples

Experimental program
Comparison scheme
Effect test

examples

[0326]Certain abbreviations and acronyms are used in describing the experimental details. Although most of these would be understood by one skilled in the art, Table 1 contains a list of many of these abbreviations and acronyms.

TABLE 1List of abbreviations and acronyms.AbbreviationMeaningAc2Oacetic anhydrideAIBN2,2′-azobis(2-methylpropionitrile)BnbenzylBnBrbenzylbromideBSAbis(trimethylsilyl)acetamideBzClbenzoyl chlorideCDIcarbonyl diimidazoleDABCO1,4-diazabicyclo[2.2.2]octaneDBN1,5-diazabicyclo[4.3.0]non-5-eneDDQ2,3-dichloro-5,6-dicyano-1,4-benzoquinoneDBU1,5-diazabicyclo[5.4.0]undec-5-eneDCAdichloroacetamideDCCdicyclohexylcarbodiimideDCMdichloromethaneDMAP4-dimethylaminopyridineDME1,2-dimethoxyethaneDMTCldimethoxytrityl chlorideDMSOdimethylsulfoxideDMTr4,4′-dimethoxytritylDMFdimethylformamideEtOAcethyl acetateESIelectrospray ionizationHMDShexamethyldisilazaneHPLCHigh pressure liquid chromatographyLDAlithium diisopropylamideLRMSlow resolution mass spectrumMCPBAmeta-chloroperbenzoic ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weight:weightaaaaaaaaaa
particle sizeaaaaaaaaaa
mass median aerodynamic diameteraaaaaaaaaa
Login to view more

Abstract

Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application 61 / 366,609 filed on Jul. 22, 2010.FIELD OF THE INVENTION[0002]The invention relates generally to methods and compounds for treating Paramyxoviridae virus infections, particularly methods and nucleosides for treating respiratory syncytial virus infections and parainfluenza virus infections.BACKGROUND OF THE INVENTION[0003]Paramyxoviruses of the Paramyxoviridae family are negative-sense, single-stranded, RNA viruses that are responsible for many prevalent human and animal diseases. These viruses comprise at least two major subfamilies, Paramyxovirinae and Pneumovirinae. The subfamily Paramyxovirina includes the human parainfluenza viruses (HPIV), measles virus and mumps virus. Although, vaccines are available to prevent measles and mumps infections, these infections caused 745, 00 deaths in 2001 so additional treatments would be desirable for susceptible populations. HPIV a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/706C07H19/04A61P31/12A61K39/395
CPCC07H19/04C07D487/04A61K31/53A61K31/675C07F9/6561A61K31/706C07H7/06A61P31/12A61P31/14A61P31/16A61P43/00Y02A50/30A61K9/0078A61K45/06
Inventor MACKMAN, RICHARD L.PARRISH, JAY P.RAY, ADRIAN S.THEODORE, DOROTHY AGNES
Owner GILEAD SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap